Boston Scientific (NYSE:BSX) today shared new clinical findings supporting its wide-ranging electrophysiology (EP) portfolio.
Boston Scientific’s BSX Electrophysiology (“EP”) sales surged 63% in the third quarter of 2025, reflecting continued share gains in the overall EP market. FARAPULSE, the company’s Pulsed Field ...
Boston Scientific’s electrophysiology business stumbled as competition from Medtronic, Johnson & Johnson, Abbott, and others in the pulsed-field ablation (PFA) space intensified. Marie Thibault, a ...
Hosted on MSN
Boston Scientific raises 2025 organic growth guidance to 15.5% amid WATCHMAN and EP momentum
CEO Michael Mahoney reported, “In third quarter '25, total company operational sales grew 19% and organic sales grew 15%, exceeding the high end of our guidance range of 12% to 14%, with sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results